The European Union publishes long-awaited changes to Annex 1.
The European Union officially released its revisions to its good manufacturing practice Annex 1 regulatory document on Aug. 25, 2022. These regulations, which pertain to manufacturing sterile drugs in the EU, are set to go into effect exactly one year after its publication, on Aug. 25, 2023.
According to the revised Annex 1: “The GMP/GDP Inspectors Working Group and the PIC/S Committee jointly recommend that the current version of annex 1, on the manufacture of sterile medicinal products, is revised to reflect changes in regulatory and manufacturing environments. The new guideline should clarify how manufacturers can take advantage of new possibilities deriving from the application of an enhanced process understanding by using innovative tools as described in the ICH Q9 and Q10 guidelines” (1).
Originally published in 2008, Annex 1 was most recently revised in 2020. Following the most recent revisions, Annex 1 sits at 59 pages; and when it was originally published it had 16.
Reference
Source: European Commission
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.